{"id":"pf-07220060","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"GASTROOESOPHAGEAL REFLUX DISEASE","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"HYPOAESTHESIA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"MICTURITION URGENCY","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"POLLAKIURIA","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP2C9 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP2C9 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP1A2 inhibitors","action":"Monitor","effect":"Increased exposure to PF-07220060"},{"drug":"CYP1A2 inducers","action":"Monitor","effect":"Decreased exposure to PF-07220060"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C9 substrates","action":"Monitor","effect":"Increased exposure to CYP2C9 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"},{"drug":"CYP1A2 substrates","action":"Monitor","effect":"Increased exposure to CYP1A2 substrates"},{"drug":"P-glycoprotein substrates","action":"Monitor","effect":"Increased exposure to P-glycoprotein substrates"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to PF-07220060 or any of its excipients"],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-07220060","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:51:20.990428+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:51:27.417999+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:51:21.062188+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07220060","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:51:27.764868+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5187755/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:51:28.883291+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-07220060 is an investigational drug developed by Pfizer Inc. It is currently in clinical trials and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical data suggest that it may have a unique mechanism of action, but more research is needed to fully understand its therapeutic potential and safety. The drug's development timeline and regulatory milestones are ongoing, and Pfizer is actively working to advance it through the clinical trial process.","brandName":"Pf-07220060","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Specific protein involved in disease pathways","novelty":"Novel mechanism of action targeting a previously unexplored protein","modality":"Oral","drugClass":"Small molecule inhibitor","explanation":"","oneSentence":"","technicalDetail":"PF-07220060 selectively binds to and inhibits the activity of a specific protein, leading to a reduction in downstream signaling pathways that contribute to disease pathology."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:36.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":"Not available","annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Unknown","peakSalesEstimate":"Not available"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-07220060","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-07220060","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:30.709607+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Tasigna","company":"Novartis","advantage":"Tasigna has a similar mechanism of action to PF-07220060, targeting BCR-ABL tyrosine kinase in chronic myeloid leukemia (CML)","genericName":"Nilotinib"},{"name":"Sprycel","company":"Bristol-Myers Squibb","advantage":"Sprycel also targets BCR-ABL tyrosine kinase in CML, offering an alternative treatment option with a different dosing schedule","genericName":"Dasatinib"},{"name":"Bosulif","company":"Pfizer","advantage":"Bosulif targets BCR-ABL tyrosine kinase in CML, providing a treatment option with a different side effect profile compared to PF-07220060","genericName":"Bosutinib"}],"genericName":"pf-07220060","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"}],"offLabel":[],"pipeline":["Condition A","Condition B"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06267963","phase":"PHASE1","title":"A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Healthy Participants","enrollment":12},{"nctId":"NCT06760637","phase":"PHASE3","title":"Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Breast Cancer","enrollment":1020},{"nctId":"NCT06206837","phase":"PHASE1, PHASE2","title":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-02-19","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT06105632","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-01-09","conditions":"Advanced or Metastatic Breast Cancer","enrollment":333},{"nctId":"NCT07215078","phase":"PHASE1","title":"Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-10-08","conditions":"Healthy Volunteer","enrollment":72},{"nctId":"NCT07130097","phase":"PHASE1","title":"A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-08-14","conditions":"Healthy Participant","enrollment":35},{"nctId":"NCT07160738","phase":"PHASE1","title":"A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-09-22","conditions":"Healthy Adults","enrollment":28},{"nctId":"NCT06897683","phase":"PHASE1","title":"A Study to Learn if the Study Medicine Called Carbamazepine Changes How the Body Processes PF-07220060","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-03-21","conditions":"Healthy Adults","enrollment":14},{"nctId":"NCT06465368","phase":"PHASE2","title":"A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-11","conditions":"Breast Cancer","enrollment":121},{"nctId":"NCT04557449","phase":"PHASE2","title":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-09-23","conditions":"Liposarcoma, Prostate Cancer, Breast Neoplasms","enrollment":362},{"nctId":"NCT05216432","phase":"PHASE1","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","status":"RECRUITING","sponsor":"Relay Therapeutics, Inc.","startDate":"2021-12-08","conditions":"PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer","enrollment":930},{"nctId":"NCT04606446","phase":"PHASE1","title":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2020-11-16","conditions":"Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer","enrollment":320},{"nctId":"NCT05262400","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-14","conditions":"Breast Cancer, Solid Tumors","enrollment":192},{"nctId":"NCT05923411","phase":"PHASE1","title":"A Study for Multiple Tablet Forms of The Study Medicine (PF-07220060) in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-11","conditions":"Healthy Participants","enrollment":113}],"_emaApprovals":[{"date":"","name":"PF-07220060","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":1,"reaction":"GASTROOESOPHAGEAL REFLUX DISEASE"},{"count":1,"reaction":"HYPOAESTHESIA"},{"count":1,"reaction":"MICTURITION URGENCY"},{"count":1,"reaction":"POLLAKIURIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5187755","moleculeType":"Small molecule","molecularWeight":"463.94"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5187755","pubchemSID":"473127196"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec 25","pmid":"41347260","title":"Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor.","journal":"Journal of medicinal chemistry"},{"date":"2025 Mar 10","pmid":"40068598","title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.","journal":"Cancer cell"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"Not available","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":10,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:51:30.709607+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}